English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

– OMC demonstrates potent, broad-spectrum in vitro activity against common Gram-positive aerobes (including methicillinand penicillin-resistant strains), Gram-negative aerobes, anaerobes, and atypical bacterial pathogens4,5 • OMC has completed phase 3 clinical development as an intravenous (IV) to once-daily oral monotherapy for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) and as oral only monotherapy for ABSSSI6-8

Analysis of the Microbiological data from the Omadacycline (OMC) Phase 3 Community-Acquired Bacterial Pneumoniae (CABP) trial: The OPTIC study